Beck LA, Thaçi D, Deleuran M, et al. - In this ongoing, multicenter, open-label extension study, researchers tested the effectiveness and safety of dupilumab treatment for up to 3 years in adults with moderate-to-severe atopic dermatitis (AD). They evaluated dupilumab treatment in adults previously registered in dupilumab trials. For this trial, individuals received dupilumab 300 mg weekly up to 148 weeks. Of 2,677 individuals registered and treated, 347 reached week 148. Nasopharyngitis, AD, upper respiratory tract infection, conjunctivitis, headache, oral herpes, and injection-site reactions were common adverse events (≥ 5% of patients) included. Such findings in terms of safety and effectiveness endorse dupilumab as a continuous long-term treatment for adults with moderate-to-severe AD.